Pharmos - Worst Pharma Stocks of 2007
Company: Pharmos
Starting stock price: $1.85
Ending stock price: $0.34
Percent Change: -81.62%
Details: In January of 2007 Pharmos announced that it's Phase II trial of cannabinor, an intravenous therapy for pain, failed to hit its primary endpoint. A separate test for relieving pain associated with molar dental extractions is still ongoing. The company announced that it cut its workforce in Israel by 15--down to 8--in an effort to restructures and conserve cash. Pharmos is also it's considering bringing in new investors to finance the subsidiary as an independent operation.
More News:
Pharmos cuts staff at Israeli subsidiary. Report
Pharmos pain drug fails in Phase II. Report
More stories about Pharmos
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
